Targeted Approach Expands Oral Options for Breast Cancer

By Gina ShawRapid advances in precision medicine are redefining treatment for hormone receptor (HR)-positive, HER2-negative breast cancer, with a growing arsenal of oral targeted therapies guided by tumor genomics, according to two leading oncology pharmacy experts.Endocrine therapy remains the foundation for HR-positive disease, but genomic testing now directs treatment sequencing. Germline BRCA1/2 mutations identify candidates for poly(adenosine diphosphate–ribose) polymerase inhibition,